Sort   by:  
 Page size 
UnknownOCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.
Not available
S-EPMC3646321 | biostudies-literature
UnknownRandomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.
Not available
S-EPMC4962710 | biostudies-literature
UnknownCosts of Planned Home vs. Hospital Birth in British Columbia Attended by Registered Midwives and Physicians.
Not available
S-EPMC4505882 | biostudies-literature
UnknownA randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.
Not available
S-EPMC6542283 | biostudies-literature
UnknownLongitudinal structural MRI-based deep learning and radiomics features for predicting Alzheimer's disease progression.
Not available
S-EPMC12330009 | biostudies-literature
UnknownRetreatment with carboplatin and paclitaxel for recurrent endometrial cancer: A retrospective study of the Memorial Sloan Kettering Cancer Center experience.
Not available
S-EPMC6461565 | biostudies-literature
UnknownPhase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early Stage Endometrial Cancer.
Not available
S-EPMC6804858 | biostudies-literature
UnknownResults of a randomized phase II trial of paclitaxel and carboplatin versus bleomycin, etoposide and cisplatin for newly diagnosed and recurrent Chemonaive stromal ovarian tumors: An NRG oncology/gynecologic oncology group study14.
Not available
S-EPMC12204228 | biostudies-literature
UnknownSubsequent therapies and survival after immunotherapy in recurrent ovarian cancer.
Not available
S-EPMC6788969 | biostudies-literature
UnknownPhase II evaluation of dalantercept in the treatment of persistent or recurrent epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.
Not available
S-EPMC6546175 | biostudies-literature
Sort   by:  
 Page size